Biological products
AssigneeUCB Pharma S.A.
InventorsAndrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
Life of this patent
Estimating the term…
Abstract
There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
Claims30
An antibody molecule having specificity for human kinase insert domain-containing receptor (“KDR”),comprising a heavy chain wherein the variable domain comprises a CDR having the sequence given as H1 in FIG. 1 (SEQ ID NO:1) for CDRH1, as H2 in FIG. 1 (SEQ ID NO:2) or residues 50-66 of SEQ ID NO:15 for CDRH2 and as H3 in FIG. 1 (SEQ ID NO:3) for CDRH3, and comprising a light chain wherein the variable domain comprises a CDR having the sequence given as L1 in FIG. 1 (SEO ID NO:4) for CDRL1, as L2 in FIG. 1 (SEO ID NO:5) for CDRL2 and as L3 in FIG. 1 (SEQ ID NO:6) for CDRL3.
An antibody molecule having specificity for human kinase insert domain-containing receptor (“KDR”), having a light chain comprising the sequence given in amino acids 22 to 235 SEQ ID NO:11.
An antibody molecule having specificity for human kinase insert domain-containing receptor (“KDR”), having a heavy chain comprising the sequence given in SEQ ID NO:57.
An antibody molecule having specificity for human kinase insert domain-containing receptor (“KDR”), having a light chain comprising the sequence given in amino acids 22 to 235 of_SEQ ID NO:11 and a heavy chain comprising the sequence given in SEQ ID NO:57.
An antibody molecule having specificity for human kinase insert domain-containing receptor (“KDR”), comprising a heavy chain wherein the variable domain comprises a CDR having the sequence given as H1 in FIG. 1 (SEQ ID NO:1) for CDRH1, as H2 in FIG. 1 (SEQ ID NO:2) or residues 50-66 of SEQ ID NO:15 for CDRH2, and as H3 in FIG. 1 (SEQ ID NO:3) for CDRH3, and comprising a light chain wherein the variable domain comprises a CDR having the sequence given as L1 in FIG. 1 (SEQ ID NO:4) for CDRL1, as L2 in FIG. 1 (SEQ ID NO:5) for CDRL2, and as L3 in FIG. 1 (SEQ ID NO :6) for CDRL3, which is a Fab fragment, a modified Fab fragment, a di-Fab fragment, a di-(modified Fab) fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, or a single chain Fv fragment.
A PEGylated di(modified Fab) in which each modified Fab comprises a light chain having the sequence given in amino acids 22 to 235 of SEQ ID NO:
- 11 and a heavy chain having the sequence given in amino acids 22 to 249 of SEQ ID NO:12.
Dependencies are inferred from the claim text.